Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pidilizumab - CureTech

Drug Profile

Pidilizumab - CureTech

Alternative Names: CT-011; MDV 9300

Latest Information Update: 04 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureTech
  • Developer American Cancer Society; Beth Israel Deaconess Medical Center; CureTech; Georgia Regents University; Hadassah Medical Organization; Northwestern University; The Ohio State University Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Delta like 1 protein inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
  • Phase I/II Glioma; Hepatitis C; Liver cancer

Most Recent Events

  • 24 May 2019 Ohio State University Comprehensive Cancer Center and CureTech completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) (IV) in USA (NCT02077959)
  • 24 Jun 2018 Biomarkers information updated
  • 12 Feb 2018 Pidilizumab is still at phase II development stage for Cancer indications in countries worldwide (Clal Biotechnology Industries pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top